AdaptHealth Corp. (AHCO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While the company exceeded free cash flow guidance and reduced debt, the decline in Wellness at Home revenue and the impact of payer mix shift are concerns. The Q&A reveals management's optimism about growth and partnerships but lacks concrete details on pilots and capitated agreements. The market cap suggests moderate sensitivity to these factors, leading to a neutral prediction as positive and negative elements balance out.
Key Financial Performance
Full Year Revenue $3.245 billion, decreased 0.5% year-over-year. Organic revenue growth was 1.7%, driven by patient census growth and operational improvements. Revenue was impacted by $92.4 million decrease due to dispositions.
Q4 Revenue $846.3 million, decreased 1.2% year-over-year. Organic revenue growth was 1.7%, driven by patient census growth and operational improvements. Revenue was impacted by dispositions.
Sleep Health Revenue $372.3 million in Q4, up 4.4% year-over-year. New starts increased by 6%, and patient census grew 4% year-over-year to 1.73 million patients.
Respiratory Health Revenue $178.2 million in Q4, up 7.8% year-over-year. Oxygen new starts increased by 4%, and vent new starts increased by 5%. Patient census for both hit all-time records.
Diabetes Health Revenue $158.5 million in Q4, down 7.4% year-over-year. Patient retention hit a new all-time record, but revenue was impacted by a shift in payer mix from commercial insurance to government payers.
Wellness at Home Revenue $137.3 million in Q4, declined 16.1% year-over-year. Decline driven by disposition of noncore assets. New starts for wheelchairs and beds increased by 6% and 5%, respectively, with patient census hitting all-time records.
Adjusted EBITDA $616.7 million for the full year, $163.1 million for Q4. Both periods included a $14.5 million legal settlement and $10 million of accelerated costs for a new capitated arrangement. Excluding these, adjusted EBITDA was in line with guidance.
Free Cash Flow $219.4 million for the full year, exceeding guidance. Q4 free cash flow was $79.3 million.
Debt Reduction $250 million reduced year-to-date, including $25 million in Q4. Net debt stood at $1.694 billion at year-end, with a net leverage ratio of 2.75x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: AI pilots for sleep order intake and conversational AI for PAP self-scheduling were introduced, significantly reducing processing and patient phone times. These pilots will be expanded in 2026.
Market Expansion: Acquisition of a Hawaii-based HME provider expanded the company's footprint to its 48th state, supporting the capitated contract in the state and establishing a base for further business opportunities.
Operational Efficiencies: Implemented a new operating model in 2025, standardizing workflows and centralizing order intake for sleep and vents, leading to improved setup times and order conversion rates. Enhanced digital patient engagement with self-scheduling features and increased myAPP users to over 327,000.
Operational Improvements: Achieved record patient census growth in sleep health, respiratory health, and wellness at home. Improved referral-to-setup times for sleep and respiratory health. Successfully onboarded the Mid-Atlantic cohort for the new capitated contract with 98% answer rates.
Strategic Shifts: Focused on debt reduction, reducing debt by $250 million in 2025. Divested noncore assets to sharpen strategic focus and redeploy capital into core businesses. Strengthened sales organization and standardized management routines to enhance sales force maturity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legal Settlement Costs: The company incurred a $14.5 million legal settlement cost in Q4 2025, which impacted profitability and cash flow.
Capitated Contract Infrastructure Costs: Over $10 million in accelerated costs were incurred to bring a new capitated arrangement live ahead of schedule, impacting adjusted EBITDA and free cash flow.
Goodwill Impairment in Diabetes Health Segment: A noncash goodwill impairment charge of $128 million was recognized, reflecting challenges in the Diabetes Health segment's estimated fair value.
Diabetes Health Revenue Decline: Net revenue in the Diabetes Health segment declined by 7.4% in Q4 2025 due to a shift in payer mix from commercial insurance to government payers, resulting in lower reimbursement rates.
Debt Levels and Leverage: Net debt stood at $1.694 billion at year-end 2025, with a net leverage ratio of 2.75x, slightly higher than the previous quarter, reflecting litigation settlement and pre-revenue contract costs.
Capitated Contract Execution Risks: The new capitated contract involves serving over 10 million patients nationwide, requiring significant infrastructure and staffing investments, posing execution risks.
CMS Documentation Requirements: New CMS documentation requirements for vents could pose challenges for smaller competitors, but also require AdaptHealth to adapt operationally.
Free Cash Flow Variability: Free cash flow is expected to be negative in Q1 2026 due to upfront infrastructure costs for the capitated contract, with improvement expected later in the year.
Acquisition and Integration Risks: The company acquired assets worth $47.6 million to support the capitated contract, which could pose integration and operational risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Net revenue for 2026 is expected to be between $3.44 billion and $3.51 billion, representing 6% to 8% growth over 2025. Organic growth is projected at 7.5% to 9.5%, offset by about 1.5% compression from acquisition and disposition revenue from previously closed deals.
Segment Growth Projections: Sleep health and respiratory health are expected to grow faster than the overall revenue growth range, while diabetes health and wellness at home are expected to remain generally flat.
Capitated Contract Revenue: Revenue from the new capitated agreement is expected to contribute 5% to 6% growth over 2025 revenue. Ramping capitated revenue is expected to add incremental year-over-year growth each quarter, peaking at low double digits by Q4 2026.
Adjusted EBITDA: Adjusted EBITDA for 2026 is projected to be between $680 million and $730 million, with a midpoint translating to approximately 20.3% adjusted EBITDA margin, a full percentage point better than 2025.
Free Cash Flow: Free cash flow for 2026 is expected to range between $175 million and $225 million. Free cash flow is anticipated to be negative $20 million to negative $40 million in Q1 2026, with improvement throughout the year as capitated revenue ramps.
First Quarter 2026 Guidance: Revenue growth of 2% to 3% over the prior year quarter is expected. Adjusted EBITDA margin is projected at approximately 16% for Q1 2026, with improving margins throughout the year.
Operational Investments: Infrastructure investments are being made to support the new capitated contract, including the acquisition of home medical equipment assets for $47.6 million. These investments are expected to ensure smooth patient transitions and will be funded through free cash flow over the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the $14.5 million legal settlement related to the civil debt collection class action from North Carolina a final settlement, and does it cover all similar or potential claims?
A:Yes, the $14.5 million settlement is final and covers all claims in that state. The company has addressed any technicalities that could be perceived as violations and decided to settle to de-risk the business.
Q:What steps has the company taken to prevent similar complaints or issues in the future?
A:The company has matured its control environment significantly since 2022, achieving a clean SOX opinion from auditors. Prior material weaknesses have been remediated.
Q:How should we think about the impact of the investment in Q4 and the margin cadence for fiscal '26?
A:Q4 guidance includes 2%-3% revenue growth and a 16% adjusted EBITDA margin. Revenue is expected to grow incrementally by 3% in Q2 and Q3, with low double-digit growth in Q4. Margins are expected to reach 20% in Q2 and increase by 1.5 points in Q3 and Q4, with full-year revenue growth at 7% and adjusted EBITDA margin just over 20%.
Q:Are the two pilots for fiscal '26 material to financial performance?
A:The pilots are not yet material in Q4 or Q1 guidance but are expected to provide operating leverage over the year, which is embedded in the guidance.
Q:What is the pipeline of capitated agreements and the opportunities going forward?
A:The company is actively pursuing both inbound and outbound opportunities for capitated agreements. These arrangements take time to develop, often over a year or more, and require infrastructure and IT systems. The company does not include potential deals in guidance until they are closed.
Q:What are the long-term growth expectations for the diabetes segment?
A:The company has improved retention rates and is building its diabetes sales force to grow CGM new starts in 2026. Pump revenues have shown low double-digit growth, and the company is optimistic about further improvements.
Q:What is the update on infrastructure readiness for the new national healthcare system partnership?
A:The company is on track with its initial outlook, having made key investments to support the February 1 start date and subsequent start dates throughout the year. Acquisitions have been made to support operations, and the company feels good about the progress.
Q:Is the current CapEx run rate expected to continue?
A:Yes, the current CapEx run rate as a percentage of revenue is expected to continue, with adjustments made for dispositions that had no CapEx.
Q:What should we know about the sleep business and its year-over-year cadence?
A:The sleep business has some noise in 2025 comparables due to changes in rental and sales mix accounting. Start growth is nearing record levels, and the company is optimistic about the business in 2026.
Q:What is the status of the DME versus pharmacy side in the diabetes segment?
A:Fewer payer policy changes have been observed, which is positive. Pump growth has been strong, supported by both pharmacy and traditional DME channels.
Q:How did the capitated contract onboarding expense in Q4 compare to guidance?
A:The onboarding expense was approximately $8 million, slightly below the $10 million previously guided. While expenses were higher than communicated, revenue from the contract is expected to grow faster than initially projected.
Q:What is the revenue contribution of the Hawaii acquisition?
A:The Hawaii acquisition contributes a run rate of just over $1 million per month, which offsets the revenue from a disposition in the home infusion assets.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of the two pilots for fiscal '26, stating they are not yet material but embedded in guidance. Additionally, while discussing the pipeline of capitated agreements, management used vague language about market interest and did not provide concrete timelines or financial expectations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI PAP
AI pilot
AdaptHealth Chief
AdaptHealth transition
CMS documentation
CMS round
Hawaii HME
Humana arrangement
census record
confidence ability
debt balance
diabetes health
history
infrastructure
maturity
model
order intake
portfolio
preparation collaboration
record diabetes
requirement
schedule
self scheduling
service delivery
setup day
sleep health
success
time
transformation
vent
wellness home
work
AHCO Transcript
AdaptHealth Corp. (AHCO) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call presents a mixed outlook. While the company exceeded free cash flow guidance and reduced debt, the decline in Wellness at Home revenue and the impact of payer mix shift are concerns. The Q&A reveals management's optimism about growth and partnerships but lacks concrete details on pilots and capitated agreements. The market cap suggests moderate sensitivity to these factors, leading to a neutral prediction as positive and negative elements balance out.
AdaptHealth Corp. (AHCO) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
AdaptHealth Corp. (AHCO) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals positive financial performance, with organic revenue growth and improved EBITDA margins. The new capitated partnership and strategic investments in infrastructure and labor are expected to drive future growth. Q&A insights highlight management's confidence in navigating competitive pressures and capitalizing on new opportunities. Although there are some execution risks, the overall sentiment is positive, with strong growth prospects and strategic positioning. Given the company's small-cap status, these factors are likely to result in a positive stock price movement over the next two weeks.
AdaptHealth Corp. (AHCO) Q2 2025 Earnings Call Transcript
Unknown8-5
Despite some positive developments, such as operational improvements and a reduction in net debt, the earnings call reveals several challenges. The Diabetes Health segment's revenue decline and the reduction in 2025 revenue and EBITDA guidance are concerning. The Q&A section indicates potential for future growth but lacks immediate catalysts. The company's significant debt and flat revenue expectations contribute to a neutral sentiment. Market cap suggests moderate reaction, with no strong short-term positive or negative drivers.
AHCO Slides
AHCO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
